$PASG News

Passage Bio Terminates Research, Collaboration And License Agreement With Gemma Bio Therapeutics

Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says

Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says

TD Cowen Downgrades Passage Bio to Hold

Chardan Capital Downgrades Passage Bio to Neutral, Lowers Price Target to $7

Oppenheimer Maintains Outperform on Passage Bio, Lowers Price Target to $15

Wedbush Downgrades Passage Bio to Neutral, Lowers Price Target to $8

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Reported Earlier: Passage Bio Receives FDA Guidance Requiring Randomized Registrational Trial For PBFT02 in FTD-GRN, Evaluates Next Steps In Clinical Development

Passage Bio shares are trading lower after the company announced the FDA did not support a single-arm trial design for its indication in the Type C meeting and instead indicated that a randomized controlled trial would be required for registrational purposes. Also, the company announced it initiated a review of strategic alternatives to maximize shareholder value.

Passage Bio shares are trading lower after the company announced the FDA did not support a single-arm trial design for its indication in the Type C meeting and instead indicated that a randomized controlled trial would be required for registrational purposes. Also, the company announced it initiated a review of strategic alternatives to maximize shareholder value.

Reported Earlier: Passage Bio Initiates Strategic Review, Exploring Mergers, Acquisitions, Partnerships, And Other Options To Maximize Shareholder Value

Passage Bio Reports Updated Data From Ongoing Phase 1/2 upliFT-D Clinical Trial Evaluating PBFT02 For Treatment Of Frontotemporal Dementia With Granulin Mutations

Passage Bio shares are trading higher after Oppenheimer initiated its coverage on the stock with an Outperform rating and announced a price target of $30.

Oppenheimer Initiates Coverage On Passage Bio with Outperform Rating, Announces Price Target of $30

Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $23

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Passage Bio Q4 EPS $(4.09) Misses $(2.68) Estimate

Passage Bio to Participate in Upcoming Investor Conferences

Chardan Capital Maintains Buy on Passage Bio, Raises Price Target to $21